BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Certara opens new office in Shanghai to focus on biopharma sector

November 12, 2020 | News

The office will allow Certara to strengthen its collaboration with customers in the rapidly growing Chinese biopharmaceutical industry



Certara, a global leader in biosimulation, recently announced the opening of a new office in Shanghai's Pudong District, China's epicentre for biopharmaceutical research and development (R&D). The office will allow Certara to strengthen its collaboration with customers in the rapidly growing Chinese biopharmaceutical industry. The company is recruiting an outstanding China-based team for business development and biopharmaceutical R&D services.

"We recognise the tremendous growth of China's biopharmaceutical industry and are thrilled to have a direct presence in China so that we can fully support our rapidly growing Chinese customer base," said William F Feehery, CEO, Certara. "Certara's extensive experience in biosimulation and our partnerships with top global biopharmaceutical companies will help foster innovation in China, accelerate time-to-market for our customers, and most importantly, improve patient outcomes."

Since 2012, Certara has been holding software training workshops in China to advance the adoption of biosimulation among biopharmaceutical companies, academic institutions, and regulatory agencies. Most recently, Certara hosted an online user group meeting on its biosimulation software with more than 400 Chinese scientists.

"We appreciate Certara's customer-focused mindset and rely on its wealth of knowledge in drug development and biosimulation," said Dr Ye Hua, CEO, BioNova Pharma, who has worked with Certara since 2015. "As more Chinese biopharmaceutical companies advance their discovery projects to clinical stages, they will need to adopt biosimulation to make data-driven decisions at all stages of the process. As the Chinese biopharma industry is still growing, Certara fills the gap for many China-based companies lacking biosimulation expertise and experience."